Millennium Increasing Integrilin Sales Force, Emphasizing Earlier Use
Millennium is increasing the size of its Integrilin sales force and encouraging earlier use of the glycoprotein IIb/IIIa inhibitor
You may also be interested in...
Millennium's Velcade agreement with Johnson & Johnson allows the biotech company to retain rights to the oncologic in the U.S., while requiring J&J to pick up nearly half of future worldwide development costs
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials